Location History:
- Wilmington, MA (US) (2022 - 2024)
- Waltham, MA (US) (2022 - 2024)
Company Filing History:
Years Active: 2022-2024
Title: The Innovative Contributions of Jared Lopes
Introduction
Jared Lopes is a notable inventor based in Wilmington, MA (US), recognized for his significant contributions to cancer treatment through innovative therapies. With a total of 5 patents, Lopes has made strides in the field of immunotherapy, focusing on enhancing the efficacy of cancer treatments.
Latest Patents
Lopes' latest patents include groundbreaking inventions such as "Compositions and methods for subcutaneous administration of cancer immunotherapy." This invention provides compositions, methods, and treatment regimens for treating cancer through periodic subcutaneous administration of a fusion protein, resulting in enhanced activation of CD8+ T-cells while minimizing effects on regulatory T cell expansion. Another significant patent is "Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors." This invention outlines a combination therapy that includes a fusion protein in conjunction with an immune checkpoint inhibitor, particularly for patients who have not achieved a complete or partial response with prior treatments.
Career Highlights
Throughout his career, Lopes has worked with prominent companies in the pharmaceutical industry, including Alkermes Pharma Ireland Limited and Mural Oncology, Inc. His work in these organizations has contributed to the development of innovative cancer therapies that aim to improve patient outcomes.
Collaborations
Lopes has collaborated with esteemed colleagues such as Heather C Losey and Raymond J Winquist, further enhancing the impact of his research and inventions in the field of cancer treatment.
Conclusion
Jared Lopes stands out as a dedicated inventor whose work in cancer immunotherapy is paving the way for more effective treatment options. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient care.